Melatonin Supplementation as Adjuvant Therapy for the Prevention of Bronchopulmonary Dysplasia in Neonates

Document Type : Original Article


1 Department of Pediatrics, Faculty of Medicine, Tanta University, Egypt

2 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt

3 Department of Biochemistry, Faculty of Pharmacy, Tanta University, Egypt


Background: Neonatal bronchopulmonary dysplasia (BPD) is a chronic chest disease caused by prolonged ventilation and oxygenation which leads to neonatal disability.
Methods: It was a prospective randomized clinical trial (RCT) (Study ID: TCTR20191211004) which was conducted in Tanta University Hospital (TUH) from July 2016 to March 2018 on 100 preterm neonates who exhibited severe respiratory distress (RD) on mechanical ventilation (MV). The studied neonates were assigned to two groups: group one which received melatonin supplementation and group two which did not. Urinary β2-microglobulin (B2M) and serum Krebs von den Lungen-6 (KL-6) levels were measured 3 and 10 days after hospitalization. The length of neonates’ stay in incubator was determined, and the number of newborns with established BPD was calculated.
Results: Significant decreases were detected in urinary B2M and serum KL-6 levels of neonates in group one who received melatonin, as compared to their counterparts in group two who did not take melatonin (P< 0.05). In addition, there was a significant decline in the length of incubator stay of neonates in group one, in comparison to that of newborns in group two (P<0.05). Moreover, neonates in group one who received melatonin displayed a significant decline in the development of established cases of BPD, as compared to group two who did not take melatonin (P<0.05).
Conclusion: As evidenced by the obtained results, melatonin supplementation could be used as adjuvant therapy for the prevention of BPD in preterm neonates. Nonetheless, further studies involving a larger number of neonates must be performed on this topic in order to recommend melatonin administration for ventilated premature neonates who are susceptible to the development of neonatal BPD.


1. Tracy MK, Berkelhamer SK. Bronchopulmonary dysplasia and pulmonary outcomes of prematurity. Pediatr Ann. 2019; 48(4):e148-53.
2. Bancalari E, Jain D. Bronchopulmonary dysplasia: 50 years after the original description. Neonatology. 2019; 115(4):384-91.
3. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7):1723-9.
4. Demirel N, Bas AY, Zenciroglu A. Bronchopulmonary dysplasia in very low birth weight infants. Indian J Pediatr. 2009; 76(7):695-8.
5. Dilli D, Özyazici A, Dursun A, Beken S. Predictive values of plasma KL-6 in bronchopulmonary dysplasia in preterm infants. Turk J Med Sci. 2017; 47(2):621-6.
6. Drüeke TB, Massy ZA. Beta2-microglobulin. Semin Dial. 2009; 22(4):378-80.
7. Kennedy KA, Cotten CM, Waterberg KL, Carlo WA. Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network. Semin Perinatol. 2016; 40(6): 348-55.
8. Perez M, Robbins ME, Revhaug C, Saugstad OD. Oxygen radical disease in the newborn revisited: Oxidative stress and disease in the newborn period. Free Radic Biol Med. 2019; 142:61-72.
9. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009; 44(4):175-200.
10. Halliwell B. Free radicals, antioxidants and human disease: curiosity, cause, or consequence? Lancet. 2009; 344(8924):721-4.
11. Banerjee S, Joshi N, Mukherjee R, Singh PK, Baxi D, Ramachandran AV. Melatonin protects against chromium (VI) induced hepatic oxidative stress and toxicity: Duration dependent study with realistic dosage. Interdiscip Toxicol. 2017; 10(1):20-9.
12. Shima Y, Nishimaki S, Nakajima M, Kumasaka S, Migita M. Urinary b-2-microglobulin as an alternative marker for fetal inflammatory response and development of bronchopulmonary dysplasia in premature infants. J Perinatol. 2011; 31(5):330-4.
13. Tsukahara H, Fujii Y, Tsuchida S, Hiraoka M, Morikawa K, Haruki S, et al. Renal handling of albumin and beta-2-microglobulin in neonates. Nephron. 1994; 68(2):212-6.
14. Nishimaki S, Sato M, An H, Shima Y, Akaike T, Yokoyama U, et al. Comparison of markers for fetal inflammatory response syndrome: fetal blood interleukin-6 and neonatal urinary B2-microglobulin. J Obstet Gynecol Res. 2009; 35(3):472-6.
15. Aly H, Elmahdy H, El-Dib M, Rowisha M, Awny M, El-Gohary T, et al. Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J Perinatol. 2015; 35(3):186-91.
16. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000; 7(6):444-58.
17. Habtemariam S, Daglia M, Sureda A, Selamoglu Z, Gulhan MF, Nabavi SM. Melatonin and respiratory diseases: a review. Curr Top Med Chem. 2017; 17(4):467-88.
18. Poggi C, Dani C. Antioxidant strategies and respiratory disease of the preterm newborn: an update. Oxid Med Cell Longev. 2014; 2014:721043.
19. Reiter RJ, Tan D, Manchester LC, Lopez-Burillo S, Sainz RM, Mayo JC. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol. 2003; 527:539-48.
20. Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E,
Sabatino G, et al. Early indicators of chronic lung disease inpreterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res. 2004; 36(4):250-5.
21. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol. 2004; 21(4):209-16.
22. Gitto E, Reiter RJ, Sabatino G, Buonocore G, Romeo C, Gitto P, et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res. 2005; 39(3):287-93.
23. Pan L, Fu JH, Xue XD, Xu W, Zhou P, Wei B. Melatonin protects against oxidative damage in a neonatal rat model of bronchopulmonary dysplasia. World J Pediatr. 2009; 5(3):216-21.
24. Bethea M, Forman DT. B2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990; 20(3):163-8.
25. Nishimaki S, Shima Y, Satoh M, An H, Hashimoto M, Nishiyama Y, et al. Urinary beta-2-microglobulin in premature infants with chorioamnionitis and chronic lung disease. J Pediatr. 2003; 143(1):120-2.
26. Zhang ZQ, Huang XM, Lu H. Early biomarkers as predictors for bronchopul-monary dysplasia in preterm infants: a systematic review. Eur J Pediatr. 2014; 173(1):15-23.
27. Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012; 271(6):589-97.
28. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest. 1999; 46(3-4):151-8.
29. Ogihara T, Hirano K, Morinobu T, Kim HS, Ogawa S, Hiroi M, et al. Plasma KL-6 predicts the development and outcome of bronchopulmonary dysplasia. Pediatr Res. 2006; 60(5):613-8.